BaseLaunch announced that Pfizer has joined the Basel-based incubator, bringing the total number of pharma company partners to seven.

Since its inception almost a decade ago, BaseLaunch has supported 27 biotech companies across various modalities and indications, with several of them having entered phase-II clinical trials. Adding Pfizer as a partner helps BaseLaunch further develop its portfolio companies, which have collectively raised over USD 1 billion.

The addition of Pfizer comes just two months after BaseLaunch announced its sixth global partner.

"BaseLaunch's roster of biotech heavy hitters continues to grow and adding new partnerships will significantly benefit our early-stage biotech ventures allowing for further growth and greater impact in the biotech industry," explained Stephan Emmerth, Director, BaseLaunch.

Through its strategic investment in BaseLaunch, Pfizer gains access to proven quality life sciences deal flow in central Europe and BaseLaunch`s company-building capabilities, while also providing expertise in biotech innovation and development of medicines with promising drug development startups.

Seven pharmaceutical companies are currently partners of BaseLaunch. In addition to Pfizer, these include AbbVie, Roche, Takeda, Novo Nordisk, Johnson & Johnson and CSL. The venture fund Pureos Bioventures is also a partner.